Whalesbook
Despite a recent surge of about 33% since April 24, driven by the appointment of Umang Vohra as Chairman and Group CEO, Jefferies has met Cohance Life Sciences with skepticism. The global brokerage downgraded its rating to 'underperform' from 'hold' and cut its price target to Rs 300 from Rs 340. This signals a belief in significant downside risk from current trading levels and challenges market optimism, suggesting underlying financial performance is at odds with recent stock momentum.
Financial Weakness Drives Downgrade
The main reason for Jefferies' stance is Cohance Life's weak fourth-quarter financial results. The company's Q4 performance fell significantly below expectations, with year-on-year declines across all business segments, notably in Specialty Chemicals. This widespread underperformance raises concerns about the company's operational health and competitive position. EBITDA margins face considerable pressure, leading Jefferies to revise downwards its Earnings Per Share (EPS) estimates for fiscal years 2027 and 2028 by 14-17%. The stock traded around ₹478-₹485 recently, levels Jefferies suggests have meaningful downside to its Rs 300 target.
Valuation and Sector Context
Cohance Life Sciences has a market capitalization between ₹18,300 and ₹18,600 crore. Its Price-to-Earnings (P/E) ratio varies significantly between reports, ranging from approximately 58 to over 130. This valuation seems high compared to the broader Indian specialty chemicals sector, which is growing strongly, projected at a CAGR of 3.65% to 8.67% through 2030. While many sector peers like Ajanta Pharma, Gland Pharma, and Wockhardt also trade at high P/E ratios, Cohance's deteriorating financial trends, flagged by MarketsMojo's 'Sell' rating, present a more concerning picture relative to its valuation.
The Indian specialty chemicals sector is a growing area seeing increased domestic and global demand in agriculture, construction, and pharmaceuticals, with the market expected to reach over $90 billion by 2030. However, Cohance's performance contrasts sharply with this positive sector trend. The company has seen substantial stock price volatility, with a 52-week high around ₹1,121 and a low near ₹267. Previously, Jefferies initiated coverage with a 'Buy' rating and a ₹1,150 target in August 2025, a stark contrast to its current 'underperform' rating and Rs 300 target. This shift reflects a significant reassessment driven by financial performance and future outlook. In October 2025, the resignation of its Managing Director, V Prasada Raju, also led to a notable stock price drop, showing investor sensitivity to leadership changes.
Key Concerns and Bear Case
Management Instability:
Umang Vohra's appointment, though notable as a former CEO of Cipla, is marred by frequent leadership changes. Vohra is reportedly the third person to head the company within a year. This constant executive turnover creates uncertainty about its strategic direction and execution. His predecessor, Vivek Sharma, stepped down as Executive Chairman for personal reasons but remains an advisor. This constant leadership change contrasts with the stability needed to manage operational and regulatory challenges.
Operational and Regulatory Issues:
Beyond leadership changes, Cohance faces other operational issues. The company's Q4 FY26 results showed a sharp decline in revenue and net profit, with EBITDA margins contracting significantly. Reports from September 2025 indicated that the company's Telangana facility received a US FDA Form 483 with six observations, including failure to review discrepancies and inadequate follow-up on drug record complaints, alongside issues with quality control procedures and equipment maintenance. Furthermore, nearly 100% of promoter shares are reportedly pledged, presenting a significant overhang. MarketsMojo rated the stock 'Sell' in April 2026, citing very negative financial trends, declining net sales, and a significant drop in PAT, despite good quality in other aspects.
Future Outlook:
Jefferies expects FY27 to remain challenging for Cohance Life Sciences, with recovery unlikely before the second half, even with a low FY26 base providing some uplift. The brokerage's reduction in FY27-28 EPS estimates by up to 17% highlights this cautious outlook. While the company notes a strong pipeline in areas like ADCs and complex chemistries, these immediate financial pressures and leadership instability pose significant hurdles for sustained growth.